GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acelyrin Inc (NAS:SLRN) » Definitions » ROA %

Acelyrin (Acelyrin) ROA % : -19.43% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Acelyrin ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Acelyrin's annualized Net Income for the quarter that ended in Mar. 2024 was $-139.89 Mil. Acelyrin's average Total Assets over the quarter that ended in Mar. 2024 was $720.09 Mil. Therefore, Acelyrin's annualized ROA % for the quarter that ended in Mar. 2024 was -19.43%.

The historical rank and industry rank for Acelyrin's ROA % or its related term are showing as below:

SLRN' s ROA % Range Over the Past 10 Years
Min: -71.83   Med: -40.9   Max: -30.68
Current: -35.59

During the past 3 years, Acelyrin's highest ROA % was -30.68%. The lowest was -71.83%. And the median was -40.90%.

SLRN's ROA % is ranked worse than
50.48% of 1553 companies
in the Biotechnology industry
Industry Median: -34.84 vs SLRN: -35.59

Acelyrin ROA % Historical Data

The historical data trend for Acelyrin's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acelyrin ROA % Chart

Acelyrin Annual Data
Trend Dec21 Dec22 Dec23
ROA %
-40.90 -30.68 -71.83

Acelyrin Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only -228.25 -18.38 -41.06 -49.36 -19.43

Competitive Comparison of Acelyrin's ROA %

For the Biotechnology subindustry, Acelyrin's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acelyrin's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acelyrin's ROA % distribution charts can be found below:

* The bar in red indicates where Acelyrin's ROA % falls into.



Acelyrin ROA % Calculation

Acelyrin's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-381.641/( (319.923+742.69)/ 2 )
=-381.641/531.3065
=-71.83 %

Acelyrin's annualized ROA % for the quarter that ended in Mar. 2024 is calculated as:

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-139.892/( (742.69+697.484)/ 2 )
=-139.892/720.087
=-19.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data. ROA % is displayed in the 30-year financial page.


Acelyrin  (NAS:SLRN) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-139.892/720.087
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-139.892 / 0)*(0 / 720.087)
=Net Margin %*Asset Turnover
=N/A %*0
=-19.43 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Acelyrin ROA % Related Terms

Thank you for viewing the detailed overview of Acelyrin's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Acelyrin (Acelyrin) Business Description

Traded in Other Exchanges
N/A
Address
4149 Liberty Canyon Road, Agoura Hills, CA, USA, 91301
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates.
Executives
Shao-lee Lin director, officer: Chief Executive Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Gil M Labrucherie officer: Interim CFO 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Beth C Seidenberg director, 10 percent owner
Henry O Gosebruch director 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Mardi Dier officer: CFO and CBO C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Mina Kim officer: Chief Legal & Admin. Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Ronald Oyston officer: Chief People Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Paul Peloso officer: Chief Medical Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Daniel J. Becker director C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036
Westlake Biopartners Fund Ii, L.p. 10 percent owner 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361
Ayurmaya Capital Management Company, Lp director, 10 percent owner, other: See Remarks 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Sean E Harper 10 percent owner AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Melanie Gloria officer: Chief Operating Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Westlake Biopartners Gp Ii, Llc 10 percent owner 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361

Acelyrin (Acelyrin) Headlines

From GuruFocus

ACELYRIN INVESTOR DEADLINE APPROACHING

By PRNewswire 01-11-2024